Tencent’s latest solution simplifies cross-border payments for Weixin users and merchants.
Updated
January 8, 2026 6:33 PM
Tencent's large penguin statue in front of a building. PHOTO: UNSPLASH
In a world where digital borders are fading faster than ever, Tencent is betting on familiarity. With the launch of TenPay Global Checkout, the company wants to make paying across countries feel as seamless as paying at home.
The new service, unveiled today, allows Weixin Mini Program merchants outside mainland China to accept a variety of local payment methods. That includes digital wallets, real-time payment networks and credit and debit cards, all through a single integration. The launch starts in Singapore and Macao SAR, where merchants can now take payments via PayNow, BOCPAY(MO), and major cards. Japan, Australia and New Zealand are next, with more regions to follow soon.
This rollout builds on the growing reach of Weixin Mini Programs, known internationally through WeChat. These small apps are built right into the platform, letting users' shop, book services and make payments without downloading separate apps. Today, there are over one million monthly active users in key overseas markets, with Mini Programs available across 92 countries and regions.
Yet, for many users abroad, paying within Mini Programs hasn’t always been simple. Foreign card restrictions, currency conversions and limited local options often made checkout a frustrating step. TenPay Global Checkout aims to change that.
“TenPay Global Checkout marks an important step in enhancing the local consumer experience. By enabling overseas Weixin Mini Program merchants to accept trusted and diversified local payment methods through one unified solution, users benefit from a more convenient and efficient payment experience. This helps merchants improve payment conversion rates, expand their user base and scale their businesses to serve a broader range of customers”, said Wenhui Yang, CEO of TenPay Global (Singapore).
What makes this move interesting isn’t just its technical simplicity—it’s the cultural bridge it builds. For users in Singapore or Japan, paying with PayNow or a local card inside Weixin feels less like an international transaction and more like an everyday purchase.
For merchants, it’s an invitation into a market that values convenience and trust. Payment familiarity, after all, often decides whether a user completes a purchase or abandons it at checkout.
The company remains focused on creating secure, connected and user-friendly payment experiences that help merchants grow and allow consumers to pay with confidence, wherever they are.
If successful, TenPay Global Checkout could quietly redefine how cross-border commerce feels—not like a transaction across regions, but a familiar tap, scan or click. In an increasingly global marketplace, that kind of familiarity might just be the next frontier in digital trust.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.